Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LIGNOSPAN FORTE vs LIGNOSPAN STANDARD
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Lidocaine and prilocaine stabilize neuronal membranes by inhibiting sodium ion influx, thereby blocking initiation and conduction of nerve impulses.
Lidocaine, the active ingredient, inhibits voltage-gated sodium channels, blocking the initiation and conduction of nerve impulses, leading to local anesthesia.
Local anesthesia for dental procedures,Local anesthesia for minor surgical procedures
Local or regional anesthesia for dental procedures,Local infiltration anesthesia,Nerve block anesthesia
Adults: 2% lidocaine with 1:100,000 epinephrine, max 7 mg/kg lidocaine (500 mg) without epinephrine or 4.5 mg/kg (300 mg) with epinephrine; for dental infiltration or nerve block, 1-2 m L per site.
2% lidocaine with 1:100,000 epinephrine: 1-5 m L (20-100 mg lidocaine) locally infiltrated; max 7 mg/kg lidocaine (up to 500 mg) per procedure. For nerve block: 1-30 m L depending on site. Epinephrine max 0.2 mg (20 m L of 1:100,000 solution) in healthy adults.
Terminal elimination half-life of lidocaine: 1.5–2 hours; in hepatic impairment or heart failure, may extend to >4 hours. For the vasoconstrictor (epinephrine), half-life is approximately 2 minutes due to rapid uptake and metabolism.
Terminal elimination half-life is approximately 1.5–2 hours in adults. Prolonged in hepatic impairment or heart failure.
Lidocaine: Hepatic metabolism via CYP1A2 and CYP3A4 to active metabolites; prilocaine: Hepatic metabolism to o-toluidine and other metabolites.
Primarily metabolized by CYP3A4 to monoethylglycinexylidide and glycinexylidide; also undergoes deethylation and hydrolysis.
Renal excretion of metabolites (predominantly 4-hydroxy-2,6-xylidine and other conjugates): ~90%; biliary/fecal: <10% as unchanged drug.
Primarily hepatic metabolism; <10% excreted unchanged in urine. Biliary/fecal excretion is minimal.
Lidocaine: ~65–75% bound to alpha-1-acid glycoprotein and albumin; epinephrine: ~50–60% bound to plasma proteins (mainly albumin).
Approximately 65% bound to plasma proteins, primarily alpha-1-acid glycoprotein (AAG) and albumin.
Lidocaine: Vd ~1.1–1.7 L/kg, indicating extensive tissue distribution; epinephrine: Vd ~0.5–1.0 L/kg (large for a catecholamine).
Volume of distribution (Vd) is approximately 0.6–1.0 L/kg. Reflects extensive tissue distribution.
Oral: <30% (extensive first-pass metabolism); intramuscular: ~100% (rapid absorption); subcutaneous infiltration: 100% (local effect); intravenous: 100%.
Bioavailability: ~100% for intravenous; approximately 85–90% for intramuscular; negligible after oral administration due to extensive first-pass metabolism.
No specific adjustment required; lidocaine is hepatically metabolized; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of metabolites.
No dose adjustment required for lidocaine; however, caution in severe renal impairment due to potential accumulation of metabolites. GFR <30 m L/min: monitor for toxicity.
Avoid in severe hepatic impairment (Child-Pugh class C); for moderate impairment (Child-Pugh B), reduce dose by 50% and monitor for toxicity.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated or use with extreme caution; reduce dose by 75% and monitor levels.
Weight-based: 1-2 mg/kg lidocaine (max 4.5 mg/kg with epinephrine) per infiltration; do not exceed 4.5 mg/kg total dose.
Lidocaine 2% with epinephrine: 0.5-2.5 mg/kg per dose (max 4.5 mg/kg lidocaine, epinephrine max 0.01 m L/kg of 1:100,000 solution). For infiltration: 1-2 m L/kg of 0.5-1% solution (without epinephrine in young infants).
Reduce dose by 50% due to decreased hepatic clearance and increased sensitivity; monitor for CNS and cardiovascular effects.
Reduce initial doses due to decreased hepatic clearance and increased sensitivity; use lowest effective dose. Maximum single dose: 200 mg lidocaine (without epinephrine) or 300 mg (with epinephrine). Monitor for CNS and cardiac toxicity.
Methemoglobinemia: Cases of methemoglobinemia have been reported, especially in infants and children. Use with caution in patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, or concurrent use with oxidizing agents.
Not available.
Risk of methemoglobinemia, especially in children <6 months; avoid use in patients with severe hepatic impairment; use caution with concurrent use of Class III antiarrhythmics; monitor for signs of systemic toxicity.
Excessive blood levels may cause CNS and cardiovascular toxicity; use lowest effective dose; caution in patients with hepatic disease, cardiac disease, or epilepsy; monitor for signs of systemic toxicity.
Hypersensitivity to amide-type local anesthetics; severe hepatic impairment; known history of methemoglobinemia; use in children under 3 years of age for certain formulations.
Hypersensitivity to lidocaine or amide-type anesthetics; severe hypotension; myasthenia gravis; severe heart block; untreated hypovolemia.
Avoid alcohol consumption for at least 24 hours after treatment as it may enhance CNS depression and reduce effectiveness. No specific food interactions; maintain normal diet but avoid hot/crunchy foods until anesthesia resolves.
No significant food interactions. Avoid citrus fruits or acidic foods immediately after injection as they may irritate the injection site.
Lignospan Forte (lidocaine 2% with epinephrine 1:100,000) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects at doses up to 6 times the human dose. However, no adequate and well-controlled studies exist in pregnant women. Lidocaine crosses the placenta. In the first trimester, risk is minimal but should be used only if clearly needed. In second and third trimesters, no known fetal harm at standard doses, but epinephrine may reduce uterine blood flow; use lowest effective dose and avoid intra-arterial injection. Avoid in preeclampsia or uteroplacental insufficiency. There is a theoretical risk of fetal bradycardia with high plasma levels.
Lignospan standard contains lidocaine and epinephrine. Lidocaine crosses the placenta and is classified as FDA pregnancy category B; no evidence of teratogenicity in animal studies, but human data are limited. Epinephrine may cause uterine vasoconstriction and reduce placental blood flow, especially in high doses or with inadvertent intravascular injection. During the first trimester, risk is minimal with standard doses. In the second and third trimesters, no known increased risk of malformations. During labor and delivery, high doses or repeated administration may lead to fetal bradycardia or neonatal depression due to lidocaine accumulation.
Small amounts of lidocaine are excreted into breast milk. The milk-to-plasma (M/P) ratio is approximately 0.3-1.0. The relative infant dose is estimated at <5% of maternal weight-adjusted dose, considered safe during breastfeeding. Epinephrine is not significantly excreted due to rapid metabolism. Use of Lignospan Forte is compatible with breastfeeding; however, monitor for infant sedation or irritability with prolonged use.
Lidocaine is excreted into breast milk in small quantities, with an estimated M/P ratio of approximately 0.4. The relative infant dose via breast milk is less than 4% of the maternal weight-adjusted dose and is considered compatible with breastfeeding. Epinephrine is not orally bioavailable. Lignospan standard is safe for use during lactation with appropriate dosing.
Pregnancy does not require dose adjustment for lidocaine; however, due to increased cardiac output and plasma volume in pregnancy, peak plasma levels of lidocaine may be lower. Epinephrine dose should be minimized as it may reduce placental perfusion. Use the smallest effective volume. In preeclampsia or hypertensive disorders, avoid or use with caution due to epinephrine's vasoconstrictive effects. No pharmacokinetic changes necessitate routine dose increase.
Pregnancy may increase lidocaine clearance due to increased hepatic blood flow and volume of distribution, but no dose adjustment is recommended for standard local anesthetic doses. However, reduced doses may be necessary in patients with preeclampsia or impaired placental perfusion. Epinephrine dose should be minimized to avoid uterine vasoconstriction.
Lignospan Forte contains lidocaine 2% with epinephrine 1:100,000. Use in dental procedures for profound anesthesia and hemostasis. Avoid in patients with severe hypertension, hyperthyroidism, or on non-selective beta-blockers due to epinephrine. Maximum dose: 7 mg/kg lidocaine with epinephrine. Aspirate before injection to prevent intravascular administration. Onset: 2-5 min; duration: 60-90 min for soft tissue, 2-4 hours for pulpal anesthesia.
Lignospan Standard is a 2% lidocaine with 1:100,000 epinephrine dental anesthetic. Aspiration before injection is critical to prevent intravascular administration. Avoid use in patients with severe heart block, uncontrolled hypertension, or hyperthyroidism due to epinephrine. Maximum dose: 4.4 mg/kg lidocaine (0.7 mg/kg epinephrine). Use with caution in patients on MAOIs, tricyclic antidepressants, or beta-blockers due to potential hypertensive crisis or reduced heart rate.
Avoid chewing on the anesthetized area until sensation returns to prevent accidental injury.,Numbness and tingling of lips, tongue, and face are normal; report any persistent numbness or pain beyond 24 hours.,Do not eat hot foods or liquids until anesthesia wears off to avoid burns.,Side effects may include dizziness, headache, or palpitations; seek medical attention if severe or prolonged.,Inform your dentist if you are pregnant, breastfeeding, or have heart disease, high blood pressure, or thyroid disorders.
Avoid eating or drinking until numbness wears off to prevent accidental biting of tongue or cheek.,Do not operate machinery or drive for at least 30 minutes after injection.,Apply ice to injection site if swelling occurs; report persistent pain or infection.,Inform your dentist of all medications, especially those for depression, high blood pressure, or heart problems.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LIGNOSPAN FORTE vs LIGNOSPAN STANDARD, answered by our medical review team.
LIGNOSPAN FORTE is a Local Anesthetic with Vasoconstrictor that works by Lidocaine and prilocaine stabilize neuronal membranes by inhibiting sodium ion influx, thereby blocking initiation and conduction of nerve impulses.. LIGNOSPAN STANDARD is a Local Anesthetic with Vasoconstrictor that works by Lidocaine, the active ingredient, inhibits voltage-gated sodium channels, blocking the initiation and conduction of nerve impulses, leading to local anesthesia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LIGNOSPAN FORTE and LIGNOSPAN STANDARD depend on the specific clinical indication. These are both Local Anesthetic with Vasoconstrictor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LIGNOSPAN FORTE is: Adults: 2% lidocaine with 1:100,000 epinephrine, max 7 mg/kg lidocaine (500 mg) without epinephrine or 4.5 mg/kg (300 mg) with epinephrine; for dental infiltration or nerve block, 1-2 m L per site.. The standard adult dose of LIGNOSPAN STANDARD is: 2% lidocaine with 1:100,000 epinephrine: 1-5 m L (20-100 mg lidocaine) locally infiltrated; max 7 mg/kg lidocaine (up to 500 mg) per procedure. For nerve block: 1-30 m L depending on site. Epinephrine max 0.2 mg (20 m L of 1:100,000 solution) in healthy adults.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LIGNOSPAN FORTE and LIGNOSPAN STANDARD in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LIGNOSPAN FORTE is classified as Category C. Lignospan Forte (lidocaine 2% with epinephrine 1:100,000) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects at doses up to 6 times. LIGNOSPAN STANDARD is classified as Category C. Lignospan standard contains lidocaine and epinephrine. Lidocaine crosses the placenta and is classified as FDA pregnancy category B; no evidence of teratogenicity in animal studies. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.